In this issue:
KEYNOTE-361: ctDNA biomarkers of response
SWOG S1011: standard vs. extended lymphadenectomy for MIBC
KEYNOTE-057: pembrolizumab for high-risk, BCG-unresponsive NMIBC without carcinoma in situ
Pathologic re-review of grade, stage & risk stratification in NMIBC
Whole-genome sequencing to detect ctDNA in urothelial carcinoma
Sapanisertib + paclitaxel in previously treated metastatic urothelial carcinoma
CORE-001: oncolytic adenoviral therapy + pembrolizumab in BCG-unresponsive NMIBC
Detectable ctDNA before radical cystectomy predictive of bladder cancer outcomes
Sitravatinib + nivolumab in advanced/metastatic urothelial carcinoma
Neoadjuvant nivolumab ± lirilumab in MIBC
Please login below to download this issue (PDF)